Glioblastoma in natalizumab‐treated multiple sclerosis patients

We present two natalizumab‐treated multiple sclerosis patients who developed glioblastoma multiforme (GBM) with variable outcomes. One patient had an isocitrate dehydrogenase (IDH)‐wildtype GBM with aggressive behavior, who declined treatment and died 13 weeks after symptoms onset. The other patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Sierra Morales, Fabian, Wright, Robert B., Novo, Jorge E., Arvanitis, Leonidas D., Stefoski, Dusan, Koralnik, Igor J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497532/
https://www.ncbi.nlm.nih.gov/pubmed/28695151
http://dx.doi.org/10.1002/acn3.428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497532/
https://www.ncbi.nlm.nih.gov/pubmed/28695151
http://dx.doi.org/10.1002/acn3.428

Ejemplares similares